FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, namely to hybrid proteins based on protein-1 of programmed cell death (hereinafter – PD-1); it can be used in medicine for the treatment, reduction, or prevention of metastasis or invasion of tumor in an object with cancer and for the treatment of an object with an infection. Hybrid protein of sPD-1-Fc protein is proposed, containing a domain of a variant of soluble PD-1 (hereinafter – sPD-1), including an amino acid substitute compared to SEQ ID NO: 1, where the specified amino acid substitute is in a position selected from a group consisting of 120, 112, 107, 104, 67, 69, 96, and 42; and where the specified domain of sPD-1 variant includes a set of amino acid G104S/S107V/A112I/A120V compared to SEQ ID NO: 1; an optional linker, and Fc domain.
EFFECT: invention provides obtainment of hybrid proteins of sPD-1-Fc variants, which bind to and antagonize PD-1 ligands.
38 cl, 42 dwg, 10 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| MODIFIED NON-NATURAL NKG2D LIGANDS WHICH SELECTIVELY DELIVER ATTACHED HETEROLOGOUS MOLECULES TO NON-NATURAL NKG2D RECEPTORS ON CAR CELLS | 2020 |
|
RU2823728C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
